AU · rank #12 · 2026-07-20
AVR
NASDAQ · $823M (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.669 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.00 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.194 |
| Analyst upside Consensus target $15.33 | +81.5% |
| Momentum acceleration 3-month minus 12-month momentum. | +3.87% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.75 |
| Gross margin TTM | +74.3% |
| 52w high | $11.06 |
| Market cap (USD) | $823M |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Anteris Technologies is a clinical-stage medical device company developing the DurAVR Transcatheter Heart Valve (THV) System for patients with aortic stenosis.
Rationale
The massive 81.5% analyst upside signal with tight consensus dispersion is supported by tangible clinical progress for DurAVR, strategic investment from Medtronic, and the rollout of the PARADIGM pivotal trial.
Material risks
- 1Clinical execution and regulatory approval risk for the PARADIGM pivotal trial, as enrollment delays or adverse patient data would block the path to market.
- 2High operating cash burn and lack of commercial revenue, necessitating dilutive capital raises once the current 12-month runway is exhausted.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.